Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial.

About this Publication
Title
Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial.
Pubmed ID
29779672 (View this publication on the PubMed website)
Publication
Urol. Oncol. 2018 Jul; Volume 36 (Issue 7): Pages 340.e1-340.e6
Authors
Gelfond J, Al-Bayati O, Kabra A, Iffrig K, Kaushik D, Liss MA
Affiliations
  • Department of Biostatistics, University of Texas Health Science Center San Antonio, San Antonio, TX.
  • Department of Urology, University of Texas Health Science Center San Antonio, San Antonio, TX.
  • Department of Urology, University of Texas Health Science Center San Antonio, San Antonio, TX; Department of Surgery, South Texas Veterans Healthcare System, San Antonio, TX. Electronic address: Liss@uthscsa.edu.
Abstract

INTRODUCTION: Identify modifiable factors contributing to renal cell carcinoma in the PCLO to target disease prevention and reduce health care costs.

METHODS: The prostate, lung, colorectal, and ovarian database were queried for the primary outcome of kidney cancer. Demographics were investigated, specifically focusing on modifiable risk factors. Statistical analysis includes the Student t-test for continuous variables, chi-squared or Fisher's exact tests for dichotomous and categorical variables for bivariate analysis. The Cox proportional hazards model was used in a multivariate time-to-event analysis.

RESULTS: We investigate existing data relating specifically to renal cancer. After missing data were excluded, we analyzed 149,683 subjects enrolled in the prostate, lung, colorectal, and ovarian trial and noted 0.5% (n = 748) subjects developed renal cancer. Age, male gender, body mass index, diabetes, and hypertension were all significant associated with renal cancer in bivariate analysis (P<0.05). Men have a significant increased risk of kidney cancer over women (hazard ratio [HR] = 1.85; 95% CI: 1.58-2.16; P<0.0001). Nonmodifiable risk factors that are associated with kidney cancer include age (HR = 1.05; 95% CI: 1.01; 1.05, P = 0.001). Modifiable risk factors include obesity measured by body mass index (HR = 1.05; 95% CI: 1.02-1.07; P<0.0001), hypertension (HR = 1.32; 95% CI: 1.13-1.54; P = 0.0004), and smoking in pack-years (HR = 1.04; 95% CI: 1.02-1.07; P = 0.0002).

CONCLUSIONS: Obesity, hypertension, and smoking are the 3 modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma.

Related CDAS Studies
Related CDAS Projects